Skip to main content
    E

    Edwards Lifesciences Corp (EW)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $107.11
    -0.04 (-0.04%)

    Market Cap: $61.61B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Edwards Lifesciences Corp (EW) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Edwards Lifesciences (EW) trades at 36.4x trailing earnings and 9.2x sales. Its P/E of 36.4x is above its 5-year median of 31.9x. Its forward P/E is 31.3x. The median P/E across 11 similar companies is 20.0x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 16.3% higher over the next year. Its free cash flow yield is 2.3%.

    MultipleValue
    P/E (trailing)36.4x
    Forward P/E31.3x
    Price to sales9.2x
    Price to book5.7x
    EV/EBITDA41.7x
    Price to FCF43.3x
    EV/FCF41.6x
    PEG2.4
    FCF yield2.3%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 7.7% above 33.8x, its P/S is 3.2% below 9.5x and its P/B is 32.9% below 8.5x.

    MultipleCurrent5-year median10-year median
    P/E36.4x31.9x33.8x
    P/S9.2x8.9x9.5x
    P/B5.7x6.2x8.5x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 28.3x in 2024 to 58.1x in 2021.

    Year endPriceP/EP/SP/B
    2025$85.2533.3x8.2x4.8x
    2024$74.0328.3x8.1x4.4x
    2023$76.2530.4x9.2x7.0x
    2022$74.6130.1x10.4x7.9x
    2021$129.5558.1x15.5x14.0x
    2020$91.2349.3x13.0x12.6x
    2019$77.7641.8x11.2x12.0x
    2018$51.0632.5x8.7x10.3x
    2017$37.5729.8x7.0x8.1x
    2016$31.2332.2x6.8x7.8x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About EW

    What is EW's forward P/E ratio?

    Edwards Lifesciences has a forward P/E ratio of 31.3x.

    Is EW stock overvalued?

    GNG's valuation label for EW is Fairly valued. Its P/E of 36.4x compares with a median of 20.0x across 11 similar companies.

    What is EW's price to sales ratio?

    Edwards Lifesciences has a price to sales ratio of 9.2x.

    What is Edwards Lifesciences's average P/E ratio over 5 years?

    Edwards Lifesciences's median P/E over the last 5 years is 31.9x, from 60 month-end values through Oct 2026.

    What is EW's PEG ratio?

    Edwards Lifesciences has a PEG ratio of 2.4.